U.S. Pharma Stock News

At Adobe MAX 2025, Adobe announced a sweeping set of new AI-powered tools across its Creative Cloud applications and revealed expanded partnerships with Google Cloud and YouTube to integrate industry-leading generative AI models and enable direct content publishing for creators. These updates include new AI assistants, improved video and image generation capabilities, enhanced enterprise content supply chain solutions, and the rollout of customizable, brand-specific AI models for both...

Sila Realty Trust recently announced its third quarter earnings, together with the declaration of a quarterly cash dividend. These back-to-back updates have given investors a closer look at both its financial performance and ongoing commitment to shareholder returns. See our latest analysis for Sila Realty Trust. After these latest earnings and dividend declarations, Sila Realty Trust’s recent 1-day share price return of 2.72% suggests investors are reacting positively to its stable results...

Liberty Global (LBTY.A) stock is drawing attention after two key developments. The company reported third-quarter results showing higher sales and a sharply reduced net loss. It also announced major changes to its board leadership. See our latest analysis for Liberty Global. Liberty Global’s share price has been on a bumpy ride lately, with a 1.96% jump in the last day following news of stronger quarterly sales and an incoming board shake-up. Despite these positive headlines, the stock is...

Genius Sports Limited recently reported its third quarter 2025 results, showing sales of US$166.28 million, up from US$120.2 million a year earlier, but recorded a net loss of US$28.81 million compared to a net income of US$12.51 million in the prior year period. Alongside these results, the company raised its full-year 2025 revenue guidance to about US$655 million, signaling management's expectation of continued strong sales momentum despite ongoing losses. We'll review how the raised...

3M (MMM) is in the spotlight after delivering a surprise operating beat for the third quarter, driven by stronger organic growth and successful new product launches. Sales climbed to multi-year highs, boosting investor optimism. See our latest analysis for 3M. 3M's share price momentum has really picked up, with a 1-month share price return of 12.7% and a solid 29.3% gain year-to-date, as upbeat Q3 results and new products have boosted sentiment despite ongoing litigation risk. When you add...

In the past week, Guardant Health announced an upsized US$350 million convertible senior notes offering and a follow-on public stock offering of over 3.3 million shares at US$90.00 per share, along with new clinical validation data showing its Guardant Reveal® blood test can assess chemotherapy effectiveness in advanced solid tumor patients months earlier than traditional methods. These developments highlight Guardant Health's efforts to secure substantial funding while supporting the...

Wondering if UiPath is actually a bargain right now? You're not alone. Many investors are eyeing the stock's value. UiPath shares have seen some volatility lately, dropping 10.5% in the last week and down 16.7% over the past month, yet they're still up nearly 10% year-to-date. Much of the recent price movement tracks with increased attention on AI automation stocks, as headlines point to expanded industry partnerships and new initiatives driving speculation and fresh interest from...

FirstEnergy is moving forward with ambitious expansion plans in West Virginia, announcing construction of a major 1,200-megawatt natural gas plant and new utility-scale solar, along with a substantial grid modernization program. See our latest analysis for FirstEnergy. Momentum is building for FirstEnergy as the company unveils its West Virginia expansion and grid modernization. The company’s share price has climbed 15.6% year-to-date, while its total shareholder return has nearly doubled...

AvePoint (AVPT) shares have been catching investors’ attention this week thanks to the release of third quarter results showing a sharp jump in both revenue and net income, along with a raised full-year outlook. See our latest analysis for AvePoint. The recent surge in AvePoint’s share price was driven by strong third quarter results and a raised outlook. However, momentum has been mixed, with a 4.88% jump in the last day offsetting a steeper share price retreat over the past month and year...

Day One Biopharmaceuticals announced it will present updated OJEMDA durability and clinical stability data from the registrational FIREFLY-1 trial at the 30th Annual Meeting & Education Day of the Society for Neuro-Oncology, with over 36 months of follow-up in pediatric low-grade glioma patients harboring BRAF alterations. The anticipation centers on new long-term clinical results and regulatory momentum for tovorafenib, highlighted by its Breakthrough Therapy, Rare Pediatric Disease, and...

Curious if Protagonist Therapeutics offers real value at today's price? You're not alone, and the market has been buzzing with activity. Shares have risen 113.5% year-to-date and are showing 79.0% gains over the past year. However, after that surge, the last month saw a dip of 4.3%. Recent news has kept investors on their toes, with notable clinical trial updates and regulatory milestones driving optimism about the company’s drug pipeline. These headlines appear to be fueling both the...

In early November 2025, Castle Biosciences reported their third quarter results, raised full-year 2025 revenue guidance to a range of US$327 million to US$335 million, and announced the commercial launch of AdvanceAD-Tx, a new gene expression test for atopic dermatitis. While recent quarterly financial results showed a moderation in sales and earnings, management's increased revenue outlook and product expansion signal confidence in future business prospects. We'll examine what Castle...

Mercury General (MCY) caught Wall Street’s attention after its third-quarter earnings surpassed expectations, helped by improved underwriting results. The company also declared a new quarterly dividend, reinforcing its commitment to shareholder returns. See our latest analysis for Mercury General. Momentum has been picking up for Mercury General, as reflected by its 30.8% year-to-date share price return and a one-year total shareholder return of 16.6%. The stock traded as high as $86.00...

Wondering if Grab Holdings is a good value right now? You are not alone, and the numbers might surprise you. The stock has soared 99.3% over the past three years and is up 34.7% in the past year. However, it did dip 2.8% in the last week. Recent partnerships and strategic expansions, such as Grab’s moves into new payment services and ride-hailing launches in Southeast Asia, have fueled optimism and driven notable price shifts. Ongoing developments keep investors and industry watchers tuned...

East West Bancorp recently reported record third-quarter 2025 results, exceeding market expectations with earnings per share of US$2.65 on revenue of US$778 million, while insiders including Vice Chairman Douglas Paul Krause and Director Molly Campbell sold shares following the announcement. The company's sustained net income growth, driven by strong deposit and loan activity, has continued despite economic and regulatory challenges, with analysts highlighting its robust US and Asia presence...

Kadant (KAI) shares have been catching the attention of investors after slipping around 2% in the past month. Many are watching to see how this performance lines up with the company’s longer-term track record, considering its history of steady growth. See our latest analysis for Kadant. After a tough stretch that saw Kadant’s share price dip over 20% in the past three months, long-term investors can still point to a strong history, with a five-year total shareholder return of more than 100%...

Earlier this month, Exact Sciences reported strong third quarter results, raised its full-year revenue outlook, and announced pivotal clinical validation data showing its Oncoguard Liver blood test outperformed ultrasound in detecting early-stage hepatocellular carcinoma. These developments underscore the company's expanding leadership in cancer diagnostics, particularly as it enhances its portfolio with innovative blood-based tests and exclusive U.S. rights to Freenome's colorectal cancer...

Arcus Biosciences recently completed a US$250.025 million follow-on equity offering of 13,700,000 shares of common stock at US$18.25 per share, bringing in Truist Securities, Mizuho Securities USA LLC, and Cantor Fitzgerald & Co. as co-lead underwriters. This significant capital raise expands Arcus Biosciences' financial flexibility and introduces new major financial partners crucial to its ongoing clinical development pipeline. We’ll examine how this major capital raise and syndicate...

DigitalBridge Group, Inc. reported third quarter 2025 results, showing revenue of US$3.82 million and net income of US$31.41 million, a shift from a net loss a year earlier, and affirmed a quarterly dividend of US$0.0100 per share payable in January 2026. The company’s move from a year-ago loss to positive earnings per share in the latest quarter highlights a significant turnaround in financial performance and ongoing confidence in operations. We’ll examine how the return to profitability...

Hub Group (HUBG) just announced its third quarter earnings, highlighting higher profits even as sales slipped from a year ago. The company also provided fresh annual guidance, giving investors a clearer sense of management’s outlook. See our latest analysis for Hub Group. Hub Group’s latest earnings update and guidance appear to have given its share price a lift, with a 1-day gain of 2.7%. However, momentum has been challenging over the longer term, as the 1-year total shareholder return is...

On November 3, 2025, Spectrum announced an expanded partnership with Harmonic to deploy advanced cOS™ vCMTS and DOCSIS 4.0 technologies across its service area, coinciding with Harmonic's third-quarter earnings release which detailed year-over-year declines in revenue and net income but guidance for fourth-quarter growth. This collaboration highlights Harmonic's market leadership in virtual broadband technology and signals ongoing momentum in large-scale operator deployments, even as the...

Lufax Holding (NYSE:LU) just made a move that could reshape how investors view its stock, appointing Xiang Ji as Co-chief Executive Officer and Tao Wu as Executive Deputy General Manager and Chief Marketing Officer. See our latest analysis for Lufax Holding. Momentum around Lufax Holding has been building, with shares up 20.92% year-to-date and a 14.23% total shareholder return over twelve months, even as the stock experienced some near-term volatility. Recent leadership changes have...

Curbline Properties Corp. recently reported third-quarter 2025 results, showing a rise in quarterly sales to US$48.47 million and net income of US$9.35 million, compared to a net loss a year earlier. Despite moving to profitability, the company lowered its full-year earnings guidance, signaling a more cautious outlook for the remainder of 2025. With Curbline Properties balancing recent profitability against reduced guidance for the year, we'll explore how this shapes its investment...

Dutch Bros (BROS) just reported quarterly earnings and revenue ahead of expectations, while also boosting its full-year guidance. The company’s outlook now includes plans for a record number of new store openings and a larger menu rollout in 2025 and 2026. See our latest analysis for Dutch Bros. Shares of Dutch Bros jumped 6.1% following the strong earnings report, capping off a robust 1-month share price return of nearly 16% and pushing the stock’s 1-year total shareholder return to 17%...